A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients with gastroenteropancreatic neuroendocrine tumors. - NA

Start Date30 Aug 2021

Sponsor / Collaborator

Camurus AB

EUCTR2021-000849-40-HU / Unknown statusPhase 3

Start Date06 Aug 2021

Sponsor / Collaborator

Camurus AB

ChiCTR2100048509 / SuspendedPhase 2IIT

A prospective, single-arm, open-label study to evaluate the efficacy and safety of Surufatinib in combination with Octreotide LAR as first line treatment in G1-G2 Gastroenteropancreatic Neuroendocrine Tumors patients

Start Date01 Aug 2021

Sponsor / Collaborator

Jiangsu Cancer Hospital

100 Clinical Results associated with Octreotide depot (GP Pharm SA)

100 Translational Medicine associated with Octreotide depot (GP Pharm SA)

100 Patents (Medical) associated with Octreotide depot (GP Pharm SA)

812

Literatures (Medical) associated with Octreotide depot (GP Pharm SA)

01 Oct 2024·Journal of Equine Veterinary Science

Concentration of Marbofloxacin in equine subcutaneous tissue fluid after subcutaneous administration in encapsulated microparticles

Article

Author: Mita, Hiroshi ; Kuroda, Taisuke ; Tamura, Norihisa ; Ohta, Minoru ; Minamijima, Yohei

Surgical-site infections (SSIs) at implant sites in horses are sometimes difficult to control with systemic antimicrobials. Because one of the likely reasons is insufficient antimicrobial concentrations, there is a need to increase these concentrations in and around the infected tissue. Marbofloxacin (MAR)-encapsulated microparticles (MAR-MPs) made of biodegradable poly (lactic-co-glycolic) acid are capable of sustained release in vitro. We examined the concentration of MAR in the subcutaneous tissue fluid at sites where MAR-MPs had been administered. On day 0, six 3- × 4-cm subcutaneous pockets were created in the neck of each of six Thoroughbred horses under sedation and local anesthesia. MAR-MPs containing 50 mg of MAR were added to each pocket, which was then sutured. On days 1, 2, 3, 4, and 7, subcutaneous tissue fluid from one pocket per horse was collected and analyzed by LC-MS/MS. From days 1 to 7, the median MAR concentration in the subcutaneous tissue fluid ranged from 17.7 (4.89-125.6) to 33.05 (15.1-71.6) µg/mL. The median concentrations in the subcutaneous tissue fluid exceeded the MIC₉₀ (the minimum inhibitory concentration that would inhibit the growth of 90 % of the tested bacterial isolates) of MAR for clinical isolates reported previously. The area of swelling at the site of administration was significantly larger on days 1 to 4 than just after administration (P < 0.05). MAR-MPs could be useful for controlling SSIs that require high antimicrobial concentrations for extended periods when they are used with strategies that reduce side effects.

01 Oct 2024·Growth Hormone & IGF Research

Medical treatment of acromegaly – When the tumor size matters: A narrative review

Review

Author: Stojanovic, Marko ; Milicevic, Mihajlo ; Doknic, Mirjana ; Miljic, Dragana

Medical treatment of acromegaly is generally positioned as a second line of treatment after pituitary adenoma surgery. With the rising availability and variety of medications for acromegaly increases our understanding of their effectiveness and safety. Volume of the published data on the impact of medical therapy on biochemical control of acromegaly, contrasts a relative lack of publications which comprehensively address pituitary tumor alterations under different drug modalities. Assessment of changes in GH-secreting adenoma volume is often overshadowed by clinicians' focus on GH and IGF-I levels during acromegaly treatment. Close analysis of studies published in the last two decades, reveals that both an increase and decrease in somatotropinoma volume are possible during treatment with any of available drugs for acromegaly. Changes in pituitary tumor size may arise from the biological nature of adenoma itself, independently of the administered medications. Therefore, an individual approach is necessary in the treatment of patients with acromegaly, based on repeated insight to their clinical, biochemical, pathological and imaging characteristics. In this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide LAR and lanreotide autogel) and the second generation (pasireotide-LAR), as well as pegvisomant (PEG) and cabergoline (CAB).

01 Sep 2024·Journal of Gastrointestinal Cancer

Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors

Article

Author: Basu, Sandip ; Chopde, Amit ; Dev, Indraja Devidas ; Kunte, Aditya ; Shrikhande, Shailesh V ; Ostwal, Vikas ; Puranik, Ameya ; Kapoor, Deeksha ; Ramaswamy, Anant ; Pandrowala, Saneya A ; Chaudhari, Vikram A ; Bhandare, Manish S ; Parghane, Rahul

AbstractIntroductionThe incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NET) has steadily increased. These tumors are considered relatively indolent even when metastatic. What determines survival outcomes in such situations is understudied.Materials and MethodsRetrospective analysis of a prospectively maintained NET clinic database, to include patients of metastatic grade 1 GEP-NET, from January 2018 to December 2021, to assess factors affecting progression-free survival (PFS).ResultsOf the 589 patients of GEP-NET treated during the study period, 100 were grade 1, with radiological evidence of distant metastasis. The median age was 50 years, with 67% being men. Of these, 15 patients were observed, while 85 patients received treatment in the form of surgery (n = 32), peptide receptor radionuclide therapy (n = 50), octreotide LAR (n = 22), and/or chemotherapy (n = 4), either as a single modality or multi-modality treatment. The median (PFS) was 54.5 months. The estimated 3-year PFS and 3-year overall survival rates were 72.3% (SE 0.048) and 93.4% (SE 0.026), respectively. On Cox regression, a high liver tumor burden was the only independent predictor of PFS (OR 3.443, p = 0.014). The 5-year OS of patients with concomitant extra-hepatic disease was significantly lower than that of patients with liver-limited disease (70.7% vs. 100%, p = 0.017).ConclusionA higher burden of liver disease is associated with shorter PFS in patients with metastatic grade I GEP-NETs. The OS is significantly lower in patients with associated extrahepatic involvement. These parameters may justify a more aggressive treatment approach in metastatic grade 1 GEP-NETs.

News (Medical) associated with Octreotide depot (GP Pharm SA)

17 Jul 2023

·www.prnewswire.com

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Favorable safety profile and effective biochemical control in 52-week trial Significant improvement of acromegaly symptoms vs. standard of care at baseline Improved patient reported treatment satisfaction, convenience, and quality of life LUND, Sweden, July 17, 2023 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced topline, interim data from an open-label, long-term safety and extension trial, ACROINNOVA 2, assessing CAM2029, octreotide subcutaneous (SC) depot, in 135 adult patients with acromegaly. These include both new patients and roll-over patients from the previous randomized controlled trial, ACROINNOVA 1, where they received treatment with CAM2029 or placebo ('treatment naïve' patients). The Phase 3 data show a favorable safety profile and robust long-term efficacy over 52 weeks of treatment with CAM2029. "We are very pleased with the Phase 3 data from ACROINNOVA 2 which shows improved biochemical and symptom control after treatment with CAM2029 versus standard of care as well as improved quality of life of patients. The new data reinforces the recent positive results from ACROINNOVA 1 and the potential of CAM2029 as a new treatment option for patients with acromegaly," says Fredrik Tiberg, Camurus' President & CEO, CSO. Acromegaly is a rare and severe chronic disease caused by a benign pituitary tumor causing excess levels of growth hormone (GH), leading to increased levels of insulin-like growth factor-1 (IGF-1). The disease causes significant morbidity, physical changes, burdensome symptoms, and diminished quality of life of patients.1-3 First-line medical treatment of acromegaly is represented by first-generation injectable somatostatin receptor ligands (SRL), octreotide and lanreotide. Interim topline data from ACROINNOVA 2 show that CAM2029 is well tolerated with a safety profile comparable to current standard of care (SoC) with first-generation SRLs. There were no severe adverse events related to CAM2029. One patient had a related serious adverse event of cholelithiasis, which resolved, and the patient continued in the trial. Two patients discontinued treatment due to adverse reactions, and one patient had an adverse reaction leading to dose reduction. In addition to a beneficial safety profile, ACROINNOVA 2 shows statistically significant improvements for multiple endpoints from baseline, with SoC and placebo (in treatment naïve patients), to the end of study treatment with CAM2029 at week 52. These improvements include: Increased IGF-1 response rate [mean (95% CI) IGF-1≤1xULN] for Full population from 49.7% to 58.4% with a difference of 8.7% [0.6%, 16.8%] New patients from 12.0% to 30.3% with a difference of 18.3% [6.5%, 30.1%] Treatment naïve patients from 20.2% to 93.8% with a difference of 73.7% [51.5%, 95.8%] CAM2029 patients had stable response rate from 92.8% to 89.4% Reduced acromegaly symptom burden during treatment with CAM2029 as measured by proportion of patients with any acromegaly symptom and the Acromegaly Index of Severity (AIS) score (sum of scores of the six acromegaly symptoms of headache, sweating, fatigue, joint pain, paresthesia, and soft tissue swelling) Increased patient and treatment satisfaction as measured by the Patient Satisfaction score and Treatment Satisfaction Questionnaire for Medication (TSQM) scores Improved quality of life as measured by the Acromegaly Quality of Life Questionnaire (AcroQoL) scores and the EuroQoL 5D-5L VAS "The data from ACROINNOVA 2 are impressive and indicate that CAM2029 has the potential to address key unmet medical needs of patients with acromegaly, including improving biochemical control, symptoms, and quality of life of patients. We also see high patient satisfaction related to the convenience of the prefilled pen and syringe and option for easy self-administration by patients", says Prof. Diego Ferone, Endocrinologist, Head of Department of Internal Medicine & Medical Specialties, IRCCS Ospedale Policlinico San Martino, University of Genova, Italy, and coordinating investigator in the trial. The interim results of ACROINNOVA 2 will be part of the regulatory submissions for CAM2029 and presented at upcoming medical meetings and in a scientific publication. About the ACROINNOVA clinical program ACROINNOVA comprises two Phase 3 studies evaluating efficacy and safety of octreotide SC depot (CAM2029). The first trial (ACROINNOVA 1, NCT04076462) is a 24-week, randomized, double-blind, multi-center, placebo-controlled Phase 3 trial that randomized 72 adult patients with acromegaly, who were on stable treatment with octreotide LAR4 or lanreotide ATG5 at enrollment. Topline results from ACROINNOVA 1 were announced on 20 June, 2023.6 Additionally, Camurus is conducting an open-label, Phase 3 long-term safety and extension trial of octreotide SC depot (ACROINNOVA 2, NCT04125836). 81 new participants have been enrolled in the trial and 54 patients have rolled over from ACROINNOVA 1 from 24 weeks treatment with CAM2029 or placebo (treatment naïve patients) to the extension part of the trial. Complete results from the 52 weeks treatment period are expected in Q2 2024. The study has been extended with an additional year of treatment and is expected to continue until 2025. About acromegaly and octreotide subcutaneous (SC) depot (CAM2029) Acromegaly is a rare, slowly progressive, and serious condition typically caused by a tumor of the pituitary gland, resulting in overproduction of growth hormone and insulin growth factor 1. This may cause physiological changes, disease symptoms, diminished quality of life, and, if untreated, premature death.7-10 The prevalence of acromegaly is estimated at about 60 cases per million.11 Octreotide SC depot is a ready-to-use octreotide for subcutaneous administration under development for treatment of acromegaly as well as gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). The product is designed for convenient, once-monthly administration using an injection pen to facilitate easy administration by patients themselves. CAM2029 has been evaluated in five completed clinical Phase 1 and 2 studies and has demonstrated an approximate five-fold increase in dose-adjusted plasma exposure compared to octreotide LAR 4. Combined with the convenience of administering CAM2029, this may offer the potential for improved efficacy, convenience, and quality of life compared to current first-line medical treatments of acromegaly, with octreotide LAR and lanreotide ATG5. These aspects are assessed in the Phase 3 ACROINNOVA program. About Camurus Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disease, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit . References Colao A., et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20. Webb SM, et al. Quality of Life in Acromegaly. Neuroendocrinology. 2016;103(1):106-111. Strasburger CJ, et al. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol. 2016 Mar;174(3):355-62. Prescribing Information SANDOSTATIN® LAR, Prescribing Information SOMATULINE®, Press release: Camurus' octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial. 20 June, 2023. Melmed S., et al. Causes and clinical manifestations of acromegaly, UpToDate, last updated May 2020, accessed May 2023. Melmed S., et al. Diagnosis of acromegaly, UpToDate, last updated Dec 2021, accessed May 2023. Katznelson L., et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51. Holdaway IM, et al. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667-74 Crisafulli S., et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinology. 2021; 185:251-63. For more information Fredrik Tiberg, President & CEO Tel. +46 (0)46 286 46 92 [email protected] Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 [email protected] This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 7:00 am CET on 17 July 2023. The following files are available for download: SOURCE Camurus AB

Clinical ResultPhase 3OligonucleotidePhase 1Phase 2

20 May 2021

·www.globenewswire.com

Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences

-- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting -- NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it will virtually present encore data from its MPOWERED™ Phase 3 clinical trial at the 23rd European Congress of Endocrinology (e-ECE) (May 22-26, 2021) and new data from the MPOWERED trial at the 30th Annual American Association of Clinical Endocrinology (AACE) Meeting (May 26-29, 2021). Oral presentations and posters for display are summarized below: e-ECE 2021 Oral PresentationTitle: A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor LigandsPresenter: Maria Fleseriu, M.D., FACE, Professor, Medicine and Neurological Surgery, Director OHSU Northwest Pituitary CenterSession Date/Time: Wednesday, May 26, 2021, 8:30 a.m. – 9:30 a.m. EDT e-ECE 2021 e-Poster PresentationsTitle: Safety Results from MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults with AcromegalyPresenter: Pamela Freda, M.D., Columbia University Session Date/Time: Monday, May 24, 2021, 8:00 a.m. – 8:30 a.m. EDT Title: Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results from the MPOWERED TrialPresenter: Nienke Biermasz, M.D., Ph.D., Leiden University Medical Center Session Date/Time: Tuesday, May 25, 2021, 8:00 a.m. – 8:30 a.m. EDT Title: Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients with Acromegaly Who Are Inadequately Controlled with MonotherapyPresenter: Maria Fleseriu, M.D., FACE, Professor, Medicine and Neurological Surgery, Director OHSU Northwest Pituitary CenterSession Date/Time: Tuesday, May 25, 2021, 8:00 a.m. – 8:30 a.m. EDT Title: Improved Acromegaly Patient Satisfaction with Oral Octreotide Capsules Compared with Injectable Somatostatin Receptor Ligands in the MPOWERED TrialPresenter: Murray B. Gordon, M.D., Allegheny General HospitalSession Date/Time: Wednesday, May 26, 2021, 8:00 a.m. – 8:30 a.m. EDT AACE 2021 Oral PresentationTitle: Improved Quality of Life and Work Productivity in Patients with Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED TrialPresenter: Nienke Biermasz, M.D., Ph.D., Leiden University Medical CenterSession Date/Time: Thursday, May 27, 2021, 1:30 p.m. – 1:45 p.m. EDT AACE 2021 Late-Breaker e-Posters - Available online via the virtual e-Poster Gallery beginning May 26Title: Effects of Prior Injectable Somatostatin Receptor Ligand Type and Dose in Patients with Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED TrialLead Author: Murray B. Gordon, M.D., Allegheny General Hospital Title: Injection Site Reactions and Their Impact in Patients with Acromegaly Receiving Injectable Somatostatin Receptor Ligands in the Phase 3 MPOWERED TrialLead Author: Murray B. Gordon, M.D., Allegheny General Hospital To register and view the full schedules as well as abstracts, visit e-ECE’s website here and AACE’s website here. Chiasma will sponsor a product theatre presentation at the AACE annual meeting titled “Understanding the Management of Acromegaly with MYCAPSSA® (octreotide) Delayed-Release Oral Capsules” on Wednesday, May 26 at 2:45 p.m. EDT. Anthony P. Heaney, M.D., Ph.D., Professor, UCLA, will lead the presentation and a live Q&A session. About the MPOWERED™ Trial The MPOWERED trial was a global, non-inferiority, randomized, open-label and active-controlled, 15-month trial intended to support approval of MYCAPSSA in the European Union. Chiasma completed enrollment of 146 adult acromegaly patients into the trial in June 2019, of which 92 patients were deemed responders to octreotide capsules per the protocol following a six-month run-in were randomized to either octreotide capsules (n=55) or injectable somatostatin receptor ligands (octreotide LAR or lanreotide autogel) (n=37), and then followed for an additional nine months. The trial was designed to evaluate the proportion of patients who maintain their biochemical response to octreotide capsules and patient-reported outcomes in patients treated with octreotide capsules, compared to patients treated with leading injectable somatostatin analogs. About MYCAPSSA INDICATION AND IMPORTANT SAFETY INFORMATION INDICATION AND USAGE MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. CONTRAINDICATIONS Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected. Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly. Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted. ADVERSE REACTIONS The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis. DRUG INTERACTIONS The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women to use an alternative non-hormonal method of contraception or a back-up method when MYCAPSSA is used with combined oral contraceptives. Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA. PREGNANCY Advise premenopausal females of the potential for an unintended pregnancy. To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or The full Prescribing Information for MYCAPSSA is available at . About Acromegaly Acromegaly typically develops when a benign tumor of the pituitary gland produces too much growth hormone, ultimately leading to significant health problems. Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision and enlargement of the hands, feet, tongue and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders and cardiac and cerebrovascular disease. Chiasma estimates that approximately 8,000 adult acromegaly patients are chronically treated with somatostatin analog injections in the United States. About Chiasma Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at . Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the data from the MPOWERED trial and the therapeutic potential of MYCAPSSA. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond the company’s control, that may cause actual events or results to differ materially from the company’s current expectations. Management’s expectations and, therefore, any forward-looking statements in this press release could be affected by risks and uncertainties. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Chiasma’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Chiasma undertakes no duty to update this information unless required by law. Investor Relations and Corporate Communications:Ashley RobinsonLifeSci Advisors, LLC617-430-7577arr@lifesciadvisors.com Media Relations:Patrick BurseyLifeSci Communications646-876-4932pbursey@lifescicomms.com

100 Deals associated with Octreotide depot (GP Pharm SA)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00104

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acromegaly	ES	GP Pharm SA	-
Bleeding esophageal varices	ES	GP Pharm SA	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCLC2017	Not Applicable	Thymic Epithelial Tumor	26	LAR octreotide and prednisone	(usscmvmfuh) = kzcghpjlys dklhpthavb (ncpcgyrlqq ) View more	Positive	16 Oct 2017
ASCO2014	Not Applicable	Prostatic Cancer	35	Octreotide LAR 30 mg + Zoledronic acid 4 mg	(phmlopyuel) = kwpeqttyxm bnbbvyvlkh (xgdhopqydl ) View more	-	20 May 2014
				Zoledronic acid 4 mg	(phmlopyuel) = baezqqhjrz bnbbvyvlkh (xgdhopqydl ) View more
ASCO2014	Not Applicable	Neuroendocrine Tumors	-	Octreotide LAR (OCT-L)	(lbzytuucmv) = gofatarwpb tvufrmbfvr (dwvaztynkf )	-	20 May 2014
				No OCT-L	(lbzytuucmv) = gmqcomgysf tvufrmbfvr (dwvaztynkf )
RADIANT-2 (ASCO2012)	Phase 3	Advanced Neuroendocrine Neoplasm	-	Octreotide LAR plus Everolimus	(uxkxktsubb) = kdsueeeuvd icwxelxxix (gtfnwspepu )	-	20 May 2012
				Placebo plus Everolimus	(uxkxktsubb) = huargidrep icwxelxxix (gtfnwspepu )
ASCO2012	Not Applicable	Metastatic Digestive System Neuroendocrine Tumor G1	337	Above-label doses of octreotide-LAR	fpehavowff(zxlrcteqla) = jkifrvbods mnaqeuvmjt (xymkjraqmh ) View more	-	20 May 2012
RADIANT-2 (ASCO2011)	Not Applicable	Advanced Neuroendocrine Neoplasm	429	Everolimus plus octreotide LAR	(wazdfdxium) = thuwabvugv oemiqypeve (bqgqetisgi )	-	20 May 2011
ASCO2010	Phase 2	Thymoma Neoadjuvant	25	Octreotide LAR 30mg	klquztbeff(ibaccizfdn) = clsfomtfoj wonqahxxdg (nytpxmykdi )	-	20 May 2010
PROMID (ASCO2009)	Not Applicable	Neoplasm Metastasis	-	Octreotide LAR 30 mg/month	(ujmgcigpqc) = uozkwudfew mntbztdyps (knachttoes ) View more	Positive	20 May 2009
				Placebo	(ujmgcigpqc) = djtxbwmkyk mntbztdyps (knachttoes ) View more
NCIC-CTG MA14 Trial (ASCO2008)	Phase 3	Breast Cancer Adjuvant	667	Tamoxifen 20mg daily	pjatmiojxa(kkavydeqwb) = zbwsdmxqwb xltqwnvvyo (pzqizrrefi ) View more	-	20 May 2008
				Tamoxifen 20mg daily + Octreotide (monthly 90mg depot injection)	pjatmiojxa(kkavydeqwb) = jmoginzywh xltqwnvvyo (pzqizrrefi ) View more
RADIANT (ASCO2007)	Phase 2	Advanced Neuroendocrine Carcinoma	60	RAD001 5 mg	(eptajgvbqu) = sofqtamxbb zdmatqjcbe (zvhmmrpifu )	-	20 Jun 2007
				RAD001 10 mg	(eptajgvbqu) = wgppxeplis zdmatqjcbe (zvhmmrpifu )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Octreotide depot (GP Pharm SA)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation